Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

This study has been terminated.
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Pharmacia and Upjohn
Information provided by:
SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier:
NCT00193024
First received: September 12, 2005
Last updated: May 2, 2011
Last verified: May 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2004
  Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)
Publications: